Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.

J Natl Cancer Inst. 2010 Nov 17;102(22):1698-705. doi: 10.1093/jnci/djq390. Epub 2010 Oct 13.

2.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
3.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
4.

Pharmacogenetics and pharmacogenomics of anticancer agents.

Huang RS, Ratain MJ.

CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. doi: 10.3322/caac.20002. Review.

5.

Pharmacogenomics in cancer therapy: is host genome variability important?

Petros WP, Evans WE.

Trends Pharmacol Sci. 2004 Sep;25(9):457-64. Review.

PMID:
15559247
6.

Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.

Bando H, Takebe N.

Jpn J Clin Oncol. 2015 Nov;45(11):1001-6. doi: 10.1093/jjco/hyv144. Epub 2015 Sep 29. Review.

7.

Pharmacogenetics and pharmacogenomics as tools in cancer therapy.

Rodríguez-Vicente AE, Lumbreras E, Hernández JM, Martín M, Calles A, Otín CL, Algarra SM, Páez D, Taron M.

Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042. Review.

8.

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.

Lesko LJ, Woodcock J.

Nat Rev Drug Discov. 2004 Sep;3(9):763-9. Review.

PMID:
15340386
9.

Pharmacogenomics. Going from genome to pill.

Service RF.

Science. 2005 Jun 24;308(5730):1858-60. No abstract available.

PMID:
15976283
10.

4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007.

Frueh FW, Salerno RA, Lesko LJ, Hockett RD.

Pharmacogenomics. 2009 Jan;10(1):111-5. doi: 10.2217/14622416.10.1.111.

PMID:
19102720
11.

Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.

Schuck RN, Grillo JA.

AAPS J. 2016 May;18(3):573-7. doi: 10.1208/s12248-016-9891-4. Epub 2016 Feb 24. Review.

12.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71. Review.

13.

Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.

Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH.

J Natl Cancer Inst. 2006 Jan 4;98(1):15-25. Review.

PMID:
16391368
14.

Enabling pharmacogenomic clinical trials through sampling.

Warner A, Nelsen A, Bhathena A, Fitzgerald K, Gilardi S, Kelso E, Knoppers B, McLeod HL, Nelson R, Uyama Y, Weisman J, Rudman A.

Pharmacogenomics. 2010 Dec;11(12):1649-54. doi: 10.2217/pgs.10.139.

PMID:
21142907
15.

Integrating pharmacogenomics into pharmacy practice via medication therapy management.

Reiss SM; American Pharmacists Association.

J Am Pharm Assoc (2003). 2011 Nov-Dec;51(6):e64-74. doi: 10.1331/JAPhA.2011.11543.

PMID:
22001957
16.

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN.

J Natl Cancer Inst. 2013 Jan 16;105(2):85-94. doi: 10.1093/jnci/djs473. Epub 2012 Nov 28. Review.

17.

Cancer pharmacogenomics: strategies and challenges.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ.

Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Epub 2012 Nov 27. Review.

18.

Accelerating identification and regulatory approval of investigational cancer drugs.

Esserman LJ, Woodcock J.

JAMA. 2011 Dec 21;306(23):2608-9. doi: 10.1001/jama.2011.1837. No abstract available.

PMID:
22187281
19.

Regulatory agency consideration of pharmacogenomics.

Pendergast MK.

Exp Biol Med (Maywood). 2008 Dec;233(12):1498-503. doi: 10.3181/0806-S-207. Epub 2008 Oct 10. Review.

PMID:
18849547
20.

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju232. doi: 10.1093/jnci/dju232. Print 2014 Sep.

Supplemental Content

Support Center